EyePoint Pharmaceuticals to participate in upcoming conferences.

EyePoint Pharmaceuticals announced that its management team will participate in three upcoming conferences: Citi's BioPharma Back to School Conference, Cantor Global Healthcare Conference, and Morgan Stanley Global Healthcare Conference. The company will hold fireside chats and one-on-one investor meetings during these events. A live webcast and archived replay of the presentations will be available on the company's website.

EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for serious retinal diseases, has announced its participation in three major upcoming investor conferences in September 2025. The company will engage in fireside chats and one-on-one investor meetings at these events, providing an opportunity for investors and stakeholders to gain insights into EyePoint's ongoing research and development efforts.

The first event, Citi's 2025 BioPharma Back to School Conference, will feature a fireside chat on September 2 at 2:30 p.m. ET. The Cantor Global Healthcare Conference will host a fireside chat on September 3 at 2:45 p.m. ET. Additionally, EyePoint will conduct one-on-one investor meetings at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9. Webcasts of the presentations will be available on the company's website for those who cannot attend in person.

EyePoint's lead product candidate, DURAVYU™, an investigational sustained delivery treatment for VEGF-mediated retinal diseases, is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with topline data anticipated in 2026. DURAVYU™ has completed a positive Phase 2 clinical trial in diabetic macular edema (DME) with Phase 3 pivotal planning underway. Despite current therapies, patients with wet AMD and DME still tend to lose vision in the long term, and wet AMD is the leading cause of vision loss among people 50 years of age and older in the United States.

EyePoint is committed to partnering with the retina community to improve patient lives while creating long-term value. The company is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts. Vorolanib, the key component of DURAVYU™, is licensed exclusively to EyePoint by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong, and Taiwan.

Investors can contact Tanner Kaufman or Jenni Lu at FTI Consulting for more information. Media inquiries can be directed to Amy Phillips at Green Room Communications.

References:
[1] https://investors.eyepointpharma.com/news-releases/news-release-details/eyepoint-announces-participation-upcoming-investor-conferences-2
[2] https://www.stocktitan.net/news/EYPT/eye-point-announces-participation-at-upcoming-investor-hona0j1rv2g4.html